Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Primary Plasma Cell Leukemia

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Primary Plasma Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2BB
cc-5013
National Cancer Institute (NCI)
Phase 3B
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3B
Evomela
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →